<DOC>
	<DOCNO>NCT01799161</DOCNO>
	<brief_summary>NSCLC tumor appropriate target active immunotherapy , non-immunogenic , indicate NSCLC stimulate spontaneous immune response . NSCLC tumor-secreted gp96-Ig ideal vaccine combine adjuvant activity polyvalent peptide specificity . Tumor secrete gp96 activates dendritic cell ( DC ) , natural killer cell ( NK ) cytotoxic T lymphocytes ( CTL ) . Tumor cell kill NK-specific mechanism , promiscuous kill CD8 CTL NKG2D , MHC restrict CD8 CTL activity . The activation DC NK tumor secrete gp96 may also counteract generation immuno-suppressive CD4 regulatory cell . Suppression adenosinergic pathway oxygen theophylline combination immunotherapy improve tumor rejection . Allogeneic , gp96-Ig secrete tumor cell use vaccine expect generate NK CTL activity patient 's autologous tumor .</brief_summary>
	<brief_title>Combination gp96-Ig Vaccine , Theophylline Oxygen Treatment Patients With Advanced , Relapsed Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This proof principle trial investigate heat shock protein gp96 Ig-secreting , allogeneic tumor cell-vaccine ( gp96-Ig vaccine ) administer combination suppression adenosinergic pathway oxygen Theophylline patient non-small cell lung cancer ( NSCLC ) . Allogeneic , culture lung adenocarcinoma cell transfected HLA A1 gp96-Ig irradiate injected intradermally patient suffer advanced , relapse , metastatic NSCLC . HLA matching require . Safety immunogenicity combine treatment study three patient cohort receive twice monthly , weekly twice weekly vaccination plus Theophylline oxygen . Immune response vaccination patient measure determine adenocarcinoma-specific CD8 CTL precursor frequency . ELI-spot assay interferon-y ( IFN-y ) do measure cytotoxic function CD8 cell challenge vitro vaccine cell autologous tumor cell . Multiparameter flow cytometry CD8 CD4 cell carry assess functional characteristic assess adenosine receptor level expression hypoxia inducible factor-1alpha . Patients randomize equal allocation ( 1:1:1 ) one three dose-schedule ( DS ) cohort define frequency vaccination . All patient receive total course dose gp96 vaccine . A total 36 patient , 12 per DS cohort , enrol . We expect accrue rate two patient per month except onset study successive enrollment space allow observation first course toxicity first several patient . ( See Section 3.3.4 detail . ) Patients follow minimum one year , thus study duration expect three year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Histologically confirm NSCLC ( squamous , adeno , large cell anaplastic , bronchoalveolar , nonsmall cell carcinoma NOS ) : stage IIIB malignant pleural effusion , stage IV , recurrent disease . At least one site measurable disease . Brain metastasis present treat must stable CT scan MRI least 4 week treatment . Patient must receive fail least one line palliative therapy ( chemotherapy biological therapy ) Age &gt; = 18 year . ECOG performance status 02 . Life expectancy &gt; = 3 month . Laboratory parameter Hemoglobin level &gt; = 10.0 ( transfusion allow necessary ) . ANC &gt; = 1,500 . Platelets &gt; = 100k . Creatinine clearance &gt; = 50 ml/min . Total direct bilirubin : &lt; 3.0 x upper institution limit normal . Liver function test : AST , ALT , AlkP &lt; 3.0 x upper institution limit normal . Signed informed consent . Active symptomatic cardiac disease congestive heart failure , angina pectoris recent myocardial infarction . Patients history condition stable take cardiac medication also exclude . Pregnant lactate woman ( negative test pregnancy require woman childbearing potential ) . Known HIV infection . Uncontrolled untreated brain spinal cord metastasis . Active infection . Concomitant steroid immunosuppressive therapy . Other active malignancy present within past three year , except basal and/or squamous cell carcinoma ( ) situ cervical cancer . Meningeal carcinomatosis . Chemotherapy , radiation therapy , antitumor therapy last three week . Immune deficiency syndrome , include follow : rheumatoid arthritis , systemic lupus erythematousus , Sjogren 's disease , sarcoidosis , vasculitis , polymyositis , glomerulonephritis . Compromised lung function : FeV1 &lt; 30 % predict value , DLCO &lt; 30 % predict value , PCO2 &gt; 45 mmHg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>gp96</keyword>
	<keyword>gp96 Vaccine</keyword>
	<keyword>AD100-gp96Ig-HLA A1</keyword>
</DOC>